Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis

被引：0
|
作者：
Gordon, Kenneth [1 ]
Leonardi, Craig [2 ]
Braun, Daniel [3 ]
Cameron, Gregory [3 ]
Erickson, Janelle [3 ]
Lebwohl, Mark [4 ]
Heffernan, Michael [3 ]
Banerjee, Subhashis [3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2014年 / 70卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P8365
引用
收藏
页码：AB183 / AB183
页数：1
相关论文
共 50 条
  • [1] IXEKIZUMAB Anti-IL-17A monoclonal antibody Treatment of psoriasis
    Haddley, K.
    DRUGS OF THE FUTURE, 2015, 40 (07) : 421 - 431
  • [2] Safety profile of ixekizumab, an anti-IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment
    Gordon, Kenneth
    Leonardi, Craig
    Braun, Daniel
    Cameron, Gregory
    Erickson, Janelle
    Lebwohl, Mark
    Heffernan, Michael
    Banerjee, Subhashis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB184 - AB184
  • [3] Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
    Blauvelt, Andrew
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 255 - 263
  • [4] Ixekizumab: an anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis
    Toussirot, Eric
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (01) : 101 - 107
  • [5] A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
    Gordon, Kenneth B.
    Leonardi, Craig L.
    Lebwohl, Mark
    Blauvelt, Andrew
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Heffernan, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (06) : 1176 - 1182
  • [6] Decreased expression of IL-17 pathway genes in blood in patients with plaque psoriasis treated with the anti-IL-17A monoclonal antibody, ixekizumab
    Krueger, J. G.
    Dow, E. R.
    Nantz, E.
    Komocsar, W. J.
    Banerjee, P.
    Leonardi, C.
    Cameron, G. S.
    Banerjee, S.
    Hoffman, R. W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S18 - S18
  • [7] Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
    Leonardi, Craig
    Matheson, Robert
    Zachariae, Claus
    Cameron, Gregory
    Li, Linda
    Edson-Heredia, Emily
    Braun, Daniel
    Banerjee, Subhashis
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (13): : 1190 - 1199
  • [8] Population Pharmacokinetics of Xeligekimab: An Anti-IL-17A Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis
    Meng, Qingheng
    Wang, Wei
    Zhang, Lingxiao
    Shi, Haiyang
    Liu, Hongxia
    Zheng, Qingshan
    Xu, Ling
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (01): : 53 - 65
  • [9] Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
    Genovese, Mark C.
    Carlier, Hilde
    Erickson, Janelle
    Braun, Daniel
    Banerjee, Subhashis
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S188 - S188
  • [10] Efficacy and safety of ixekizumab over four years of open-label treatment in a Phase 2 study in chronic plaque psoriasis
    Gordon, K.
    Leonardi, C.
    Blauvelt, A.
    Zachariae, C.
    Cameron, G.
    McKean-Matthews, M.
    Ridenour, T.
    Lebwohl, M.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 39 - 39
12345